Phase III trial of docetaxel cisplatin 5-fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome.

ABSTRACT:

SUBMITTER: Ju WT 

PROVIDER: S-EPMC7968883 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature